ATRA Logo

Atara Biotherapeutics, Inc. (ATRA) 

NASDAQ
Market Cap
$63.98M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
558 of 963
Rank in Industry
304 of 552

Largest Insider Buys in Sector

ATRA Stock Price History Chart

ATRA Stock Performance

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Insider Activity of Atara Biotherapeutics, Inc.

Over the last 12 months, insiders at Atara Biotherapeutics, Inc. have bought $0 and sold $269,243 worth of Atara Biotherapeutics, Inc. stock.

On average, over the past 5 years, insiders at Atara Biotherapeutics, Inc. have bought $347,627 and sold $1.04M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 90,980 shares for transaction amount of $28,186 was made by Gallagher Carol Giltner (director) on 2023‑11‑14.

List of Insider Buy and Sell Transactions, Atara Biotherapeutics, Inc.

2024-11-18SalePresident and CEO
1,664
0.0286%
$11.20$18,6330.00%
2024-11-18SaleEVP, CFO and COO
1,364
0.0234%
$11.20$15,2740.00%
2024-11-18SaleEVP, Chief Regulatory Officer
1,000
0.0172%
$11.20$11,1980.00%
2024-08-16SalePresident and CEO
3,038
0.053%
$6.63$20,139-0.07%
2024-08-16SaleEVP, Chief Sci. & Tech Officer
1,821
0.0318%
$6.63$12,072-0.07%
2024-08-16SaleEVP, Chief Legal Officer
1,158
0.0202%
$6.63$7,677-0.07%
2024-08-16SaleEVP, CFO
1,070
0.0187%
$6.63$7,093-0.07%
2024-08-16SaleEVP, Global Head RA & Quality
963
0.0168%
$6.63$6,384-0.07%
2024-05-16SalePresident and CEO
81,506
0.0671%
$0.62$50,289-35.59%
2024-05-16SaleEVP, Chief Sci. & Tech Officer
42,899
0.0353%
$0.62$26,469-35.59%
2024-05-16SaleEVP, Chief Legal Officer
32,401
0.0267%
$0.62$19,991-35.59%
2024-05-16SaleEVP, CFO
28,648
0.0236%
$0.62$17,676-35.59%
2024-05-16SaleEVP, Global Head RA & Quality
25,750
0.0212%
$0.62$15,888-35.59%
2024-03-04SalePresident and CEO
24,844
0.0185%
$0.72$17,888-35.06%
2024-03-04SaleEVP, Chief Sci. & Tech Officer
10,746
0.008%
$0.72$7,737-35.06%
2024-03-04SaleEVP, Chief Legal Officer
10,044
0.0075%
$0.72$7,232-35.06%
2024-03-04SaleEVP, CFO
6,679
0.005%
$0.72$4,810-35.06%
2024-03-04SaleEVP, Global Head RA & Quality
3,879
0.0029%
$0.72$2,793-35.06%
2023-11-16SalePresident and CEO
20,409
0.0161%
$0.39$7,939+19.73%
2023-11-16SaleEVP, Chief Sci. & Tech Officer
8,856
0.007%
$0.39$3,445+19.73%

Insider Historical Profitability

60.7%
Nguyen AnhCoPresident and CEO
77454
1.3447%
$11.1107
Touchon PascalPresident and CEO
70127
1.2175%
$11.11022
Murugan AmarEVP, Chief Legal Officer
26827
0.4658%
$11.11014
Hyllengren Eric JEVP, CFO and COO
23392
0.4061%
$11.1107
Henrich JillEVP, Chief Regulatory Officer
19378
0.3364%
$11.1106
Domain Partners VIII, L.P.10 percent owner
2141542
37.1812%
$11.1110+169.68%
MARCUS JOEL Sdirector
888355
15.4235%
$11.1133+73.99%
DOBMEIER ERICdirector
563325
9.7804%
$11.1140<0.0001%
Gallagher Carol Giltnerdirector
459418
7.9764%
$11.11418+129.11%
Dupont JakobEVP, Head of R&D
290794
5.0487%
$11.11012
Ciechanover Isaac E.Chief Executive Officer
290687
5.0469%
$11.110187
Banard Charlene A.EVP, Chief Technical Officer
276010
4.792%
$11.1101
Haqq ChristopherEVP, R&D & Chief Scientific Of
271943
4.7214%
$11.11035
Soffer GadEVP & Chief Strategy Officer
256236
4.4487%
$11.11018
HEIDEN WILLIAM Kdirector
209000
3.6286%
$11.1110
Koppikar UtpalChief Financial Officer
181978
3.1595%
$11.11121<0.0001%
Joshi ManherEVP, Chief Medical Officer
171284
2.9738%
$11.1102
Yarema KristinChief Commercial Officer
125882
2.1855%
$11.1121+0.58%
Newell JoeChief Operations Officer
113097
1.9636%
$11.11035
Clark Mitchall G.EVP & Chief R & QA Officer
107972
1.8746%
$11.11013
MCGRATH JOHNEVP & Chief Financial Officer
88762
1.5411%
$11.11025
Turner Heather DFormer EVP, GC & Sec.
69494
1.2065%
$11.1102
Fust Matthew Kdirector
31500
0.5469%
$11.1102
Porter DerrellSVP, Head of Global Commercial
21688
0.3765%
$11.1103
DP VIII Associates, L.P.10 percent owner
15890
0.2759%
$11.1110+169.68%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Ecor1 Capital Llc$7.06B207.3110.17M+0.99%+$69.4M49.51
Redmile Group$6.43B188.889.26M+1.72%+$108.86M65.63
BlackRock$4.74B139.36.83M-3.61%-$177.48M0.1
Bank of America$4.57B134.186.58M+3,379.43%+$4.44B0.44
Citadel Advisors LLC$4.52B132.786.51M+2,375.59%+$4.34B2.58
The Vanguard Group$3.48B102.225.01M-25.02%-$1.16B0.06
T. Rowe Price$3.44M101.14.96M+8,916.29%+$3.4M<0.0001
Boxer Capital, LLC$2.88B84.624.15MNew+$2.88B59.03
Acadian Asset Management$1.83M53.82.64M+49.45%+$605,541.080.01
AQR Capital$1.82B53.532.63M-10.46%-$212.95M2.84
State Street$1.73B50.752.49M-10.6%-$204.84M0.07
Geode Capital Management$1.5B44.022.16M+0.39%+$5.86M0.13
Tang Capital Management, LLC$1.3B38.331.88MNew+$1.3B4.89
Woodline Partners LP$1.23B36.191.77MNew+$1.23B10.51
JPMorgan Chase$937.74M27.551.35M-38.24%-$580.76M0.08
Morgan Stanley$934.21M27.451.35M-24.94%-$310.39M0.07
Staley Capital Advisers, Inc.$694M20.391M0%+$024.58
J. Goldman & Company$684.74M20.12986,651New+$684.74M23.8
Renaissance Technologies$680,000.0019.99980,385+57.39%+$247,945.78<0.01
Northern Trust$590.47M17.35850,821+0.64%+$3.74M0.1
Charles Schwab$528.38M15.52761,360+2.18%+$11.25M0.12
Shay Capital Llc$304.32M8.94438,506New+$304.32M47.39
Td Asset Management Inc$303.14M8.91436,800New+$303.14M0.27
Fidelity Investments$285.01M8.37410,678-11.63%-$37.5M0.02
Millennium Management LLC$250.7M7.37361,245-87.63%-$1.78B0.16
BNY Mellon$244.64M7.19352,513-10.7%-$29.32M0.05
The Manufacturers Life Insurance Company$216.64M6.37312,163+1,140.02%+$199.17M0.2
Royal Bank of Canada$200M5.87287,637+843.23%+$178.8M0.05
Goldman Sachs$169.51M4.98244,257-58.05%-$234.52M0.03
AllianceBernstein$116.04M3.41167,2000%+$00.04
RhumbLine Advisers$102.4M3.01147,574+1.49%+$1.5M0.09
Schonfeld Group$102.02M3147,000New+$102.02M0.58
Savant Capital Management$91.48M2.69131,811New+$91.48M1.36
Group One Trading$89.19M2.62128,522-8.56%-$8.35M1.18
UBS$73.89M2.17106,465-97.12%-$2.49B0.02
Private Advisor Group$66.39M1.9595,6610%+$00.45
Vontobel Holding Ltd$55.52M1.6380,0000%+$00.42
Barclays$47,000.001.3867,661-49.07%-$45,280.77<0.0001
Jane Street Capital$43.48M1.2862,651-52.6%-$48.25M0.04
American International Group$33.13M0.9747,731-0.85%-$284,537.300.11
State of Wisconsin Investment Board$31.44M0.9245,301+0.22%+$69,400.230.08
Marshall Wace$29.15M0.8642,242-85.56%-$172.67M0.03
Delap Wealth Advisory Llc$28.82M0.8541,533New+$28.82M11.72
Wells Fargo$27.75M0.8239,988+13.07%+$3.21M0.01
New York State Common Retirement Fund$28,000.000.8139,681+0.35%+$98.79<0.0001
Deutsche Bank$25.08M0.7436,353-5.29%-$1.4M0.01
Invesco$23.95M0.734,507-0.1%-$24,984.150.01
Voya Investment Management LLC$23.43M0.6933,767-17.32%-$4.91M0.03
Atom Investors Lp$21.8M0.6431,408New+$21.8M1.42
State Board of Administration of Florida$90.32M0.6431,145+23.79%+$17.36M0.16
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.